Nanocrystalline Epstein-Barr virus decoys.
A novel biotechnology is introduced by way of the successful synthesis of nanocrystalline Epstein-Barr virus (EBV) decoys having specific in vivo immunogenic activity. Assembled from ultrafine surface modified tin oxide and purified DNA-free isolated EBV envelope proteins, the decoys consisted of less than 150 nm units whose electrophoretic mobilities were similar to whole EBV; whose outer coats were strongly immunoreactive with murine monoclonal anti-EBV antibodies; and which elicited immunospecific neutralizing anti-EBV antibodies in the rabbit. The development of this carrier technology for vaccine preparations is suggested.